Lennart Kühl

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release

R. Kontermann, Nadine Aschmoneit, Lennart Kühl, 2021, Journal for ImmunoTherapy of Cancer.

Triple targeting of HER receptors overcomes heregulin-mediated resistance to EGFR blockade in colorectal cancer.

Monilola A. Olayioye, R. Kontermann, M. Schwab, 2022, Molecular cancer therapeutics.

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)

R. Kontermann, M. Siegemund, Nadine Aschmoneit, 2022, Oncoimmunology.

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

Monilola A. Olayioye, R. Kontermann, M. Olayioye, 2021, mAbs.

The eIg technology to generate Ig-like bispecific antibodies

R. Kontermann, Nadine Aschmoneit, Lennart Kühl, 2022, mAbs.

eIg-based bispecific T-cell engagers targeting EGFR: Format matters

R. Kontermann, Nadine Aschmoneit, Lennart Kühl, 2023, mAbs.

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

R. Kontermann, Nadine Aschmoneit, Lennart Kühl, 2021, Scientific Reports.